• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-analysis: Are Biologics for Chronic Inflammatory Disease Associated with Worse Neonatal Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Chronic inflammatory diseases (CIDs) include rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease (IBD)
  • Biologic medications, particularly the TNF-α inhibitors , are used to treat CID, a subset of autoimmune diseases
    • Safety regarding use is unclear
  • O’Byrne et al. (BJOG, 2022) examined pregnancy outcomes in women with CID exposed to biologics during pregnancy

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • Cohort | Case-control | Cross-sectional studies | Case series
    • Studies that assessed the association between biologics used for CID in  pregnancy and maternal and neonatal outcomes
  • Exposures
    • Treated: women with CID prescribed biologics
    • Disease matched: women with CID without a biologic prescription
    • Disease free: women without a diagnosis of CID
  • Study design
    • A meta-analysis of proportions using a random-effects model was used to pool outcomes
    • Linear regression analysis was used to compare the mean of proportions of outcomes across exposure groups using the ‘treated’ group as the reference category
    • GRADE criteria was used to assess the overall certainty of evidence
  • Primary outcome
    • Pregnancy outcomes

RESULTS:

  • 35 studies | 11,172 pregnancies
  • There were no significant differences in outcomes between the groups
    • Congenital malformations (P=0.238)
      • Treated: pooled proportions 0.04 (95% CI, 0.03 to 0.04)
      • Disease matched: 0.04 (95% CI, 0.03 to 0.05)
    • Preterm delivery (P=0.250)
      • Treated: 0.04 (95% CI, 0.10 to 0.14)
      • Disease matched: 0.10 (95% CI, 0.09 to 0.12)
    • Severe neonatal infection (P=0.970)
      • Treated: 0.05 (95% CI, 0.03 to 0.07)
      • Disease matched: 0.05 (95% CI, 0.02 to 0.07)
    • Low birth weight (P=0.241)
      • Treated: 0.10 (95% CI, 0.07 to 0.12)
      • Disease matched: 0.08 (95% CI, 0.07 to 0.09)
    • Miscarriage (P=0.078)
      • Treated: 0.13 (95% CI, 0.10 to 0.15)
      • Disease matched: 0.08 (95% CI, 0.04 to 0.11)
    • Preeclampsia (P=0.193)
      • Treated: 0.01 (95% CI, 0.01 to 0.02)
      • Disease matched: 0.01 (95% CI, 0.00 to 0.01)
  • Certainty of findings overall were low to very low

CONCLUSION:

  • Women with CID in pregnancy treated with biologics did not have worse neonatal outcomes compared to untreated disease-matched controls, or disease-free controls, although certainty of findings was low
  • The authors state

With over 11,172 pregnancies exposed to biologic medications, our study shows no evidence of harm for the fetus or the mother

More evidence is required to prove the likely protective effects of these medications from unwanted outcomes that disease flare may cause in CID-affected pregnancies

This is important for gastroenterologists, rheumatologists and obstetricians alike when reassuring women regarding continuation of treatment throughout pregnancy and for refractory disease during childbearing years

Learn More – Primary Sources:

Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: a systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Use of Biologics in Pregnant Women with IBD: Is there an Increased Risk for Infantile Infections?
Inflammatory Bowel Disease and Biologic Therapies in Pregnancy
Can Tighter Control Improve the Course of Crohn’s Disease?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site